More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...

The 340B Drug Pricing Program was created in 1992 and allows hospitals and clinics that treat a large population of low-income and uninsured patients to buy outpatient prescription drugs at a discount ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

The 340B Drug Pricing Program (“340B Program”) space continues to be a hive of activity. While 340B stakeholders continue to litigate ongoing manufacturer contract pharmacy restrictions, states ...

On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

Washington, D.C. The 340B Drug Pricing Program has grown immensely since the Affordable Care Act (ACA) was passed in 2010. New research published in the journal INQUIRY finds that the growth in the ...

New York state lawmakers are considering a bill that'd make it easier for big hospital systems to siphon off financial aid that's meant for poor patients. The bill involves the 340B Drug Pricing ...